glp 1 drugs mechanism GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes Glucagon-like peptide-1 (GLP-1) receptor agonists
Description
Results Seven trials (6609 participants) were included
The primary goal of this article is to emphasize the extensive benefits of using GLP-1RAs in treating a broad spectrum of diseases, such as obesity, cardiovascular diseases, non-alcoholic fatty liver disease (NAFLD), neurodegenerative diseases, musculoskeletal inflammation, and various forms of cancer
Once weekly
A new FDA-approved obesity pill could offer a lower-cost alternative to injectable GLP-1 drugs like Ozempic and Mounjaro
they may also have direct effects in the brain (animal studies show neuroprotection and reduced amyloid/tau pathology)
